Vaxart Adjourns Annual Meeting for Stockholder Voting

Vaxart ( (VXRT) ) has issued an update.

On May 21, 2025, Vaxart announced the adjournment of its 2025 annual meeting of stockholders to June 2, 2025, to allow additional time for stockholders to vote on proposals. The company’s board believes that approving a reverse stock split proposal is crucial for maintaining Nasdaq listing compliance and attracting investor interest. Stockholders who have already voted do not need to recast their votes, and proxies submitted will remain valid unless revoked.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s stock score is primarily driven by strong revenue growth and strategic initiatives such as clinical trial advancements and the proposed reverse stock split. However, significant challenges in profitability, cash flow management, and technical indicators suggest bearish momentum. The risk of NASDAQ delisting also weighs heavily on the stock. While strategic initiatives and cash management efforts offer some hope for future stability, current risks remain substantial.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered in pill form, which allows for storage and shipping without refrigeration and eliminates the risk of needle-stick injury. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).

Average Trading Volume: 2,084,656

Technical Sentiment Signal: Sell

Current Market Cap: $115.9M

For an in-depth examination of VXRT stock, go to TipRanks’ Stock Analysis page.